News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Aleix Prat

Articles by Aleix Prat

TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC

ByMario Campone,Louise Emmett,Dejan Juric,Debasish Tripathy,Sonia Pernas,Monica Zuradelli,Kevin Perraud,Aleix Prat

June 21st 2025

12 TIP HARMONIA SOLTI-2101/ AFT-58: A Head-to-Head Phase III Study Comparing Ribociclib (RIB) and Palbociclib (PAL) in Patients (pts) With Hormone Receptor– Positive/HER2-Negative/HER2- Enriched (HR+/HER2−/HER2-E) Advanced Breast Cancer (ABC)

ByLisa A. Carey, MD,Tomas Pascual,Daniel Stover,Astrid Thuerigen,Charles Perou,Eva Ciruelos,Ana Casas,Patty Spears,Estelle Roux,Faye Su,Hullin Hu,Yen-Shen Lu,Sara M. Tolaney, MD, MPH,Ann H. Partridge, MD, MPH,Guillermo Villacampa,Juan Manuel Ferrero-Cafiero,Aleix Prat

April 28th 2023

Latest Updated Articles

TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC
Published: June 21st 2025 | Updated:

Trending on CancerNetwork

MARIPOSA Final OS Results in Asia Population Yield Meaningful Improvement in EGFR NSCLC

Novel Treatment Displays Tolerability in Relapsed/Refractory B-Cell ALL

3 Things You Should Know About Future Directions for BsAbs and ADCs in NSCLC

T-DM1 Confers Lower Cardiotoxicity Risk in HER2+ Advanced Breast Cancer

Surveying the Treatment Landscape for EGFR-Mutated Lung Cancer

© 2025 MJH Life Sciences^®

All rights reserved.